Northwest Biotherapeutics, Inc. (NWBO) is a clinical-stage biotechnology company focused on developing personalized immune therapies for cancer. Their lead product platform, DCVax®, utilizes the patient's own dendritic cells, a type of immune cell, to mobilize the entire immune system to attack cancer. The company is primarily advancing DCVax-L for glioblastoma multiforme (GBM), the most aggressive and lethal form of brain cancer, and DCVax-Direct for all types_of inoperable solid tumors. Their approach aims to create tailored treatments with potentially fewer side effects than conventional therapies.
Serves as the central hub for corporate administration, strategic planning, clinical trial oversight, regulatory affairs, and investor relations.
The headquarters is situated in a modern office building, providing a professional environment conducive to managing complex biotechnology operations and research collaborations.
The work culture is likely intensive and mission-driven, characterized by scientific rigor, a focus on innovation in cancer treatment, and collaboration among a relatively small, specialized team.
Its location in Bethesda provides strategic advantages, including proximity to key regulatory bodies, research institutions, and a skilled talent pool in the biotech sector.
Northwest Biotherapeutics supports its global clinical trial programs and prepares for potential commercialization primarily through its headquarters in the US (Maryland) and key manufacturing and operational facilities in the United Kingdom and Belgium. These locations enable research, development, manufacturing, and regulatory interactions across North America and Europe, which are the main regions for its ongoing and planned clinical studies for DCVax therapies.
4800 Montgomery Lane, Suite 800
Bethesda
Maryland
USA
Address: Sawston Trade Park, London Road, Sawston, Cambridge, CB22 3EE, UK
Supports clinical development and future commercial manufacturing for the UK and European markets, ensuring compliance with MHRA (UK) and potentially EMA (EU) regulatory requirements.
Address: Industriepark B7, 2220 Heist-op-den-Berg, Belgium
Enhances manufacturing capacity and logistical reach within continental Europe, supporting clinical trials and preparing for broader market access.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Northwest Biotherapeutics' leadership includes:
Northwest Biotherapeutics has been backed by several prominent investors over the years, including:
Northwest Biotherapeutics has a relatively small and stable core executive team. Publicly available information and press releases over the last 12-18 months do not indicate significant high-profile executive hires or departures. Leadership continuity appears to be a feature.
Discover the tools Northwest Biotherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Northwest Biotherapeutics likely uses common corporate email formats. The most probable format is first initial followed by last name.
[first_initial][last]@nwbio.com
Format
lpowers@nwbio.com
Example
80%
Success rate
GlobeNewswire • March 7, 2024
Northwest Biotherapeutics announced progress on its Marketing Authorization Application (MAA) to the MHRA in the UK and its New Drug Application (NDA) to the FDA in the US for DCVax-L for Glioblastoma. The company is actively addressing queries from regulatory agencies....more
GlobeNewswire • October 26, 2023
Northwest Biotherapeutics announced that its Sawston, UK manufacturing facility received crucial certifications from the Medicines and Healthcare products Regulatory Agency (MHRA), including Good Manufacturing Practice (GMP) certification and Manufacturer's Importation Authorisation (MIA)....more
JAMA Oncology • November 10, 2022
The results of the Phase 3 clinical trial of DCVax-L for newly diagnosed and recurrent glioblastoma (GBM) were published in JAMA Oncology, showing extended survival in certain patient populations. This publication was a significant milestone for the company....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Northwest Biotherapeutics, are just a search away.